Regulation of primary metastasis in high grade serous ovarian cancer
Project Number5F30CA260791-04
Contact PI/Project LeaderBERGSTEN, TOVA
Awardee OrganizationUNIVERSITY OF ILLINOIS AT CHICAGO
Description
Abstract Text
Project Summary/Abstract
High grade serous ovarian cancer (HGSOC) is both the most common and most lethal ovarian cancer
histotype. Though HGSOC has been long thought to originate in the ovary, recent evidence now suggests that
HGSOC precursor lesions in fact originate in the fallopian tube. Further, select dysplastic cells from the
fallopian tube disseminate from these precursor lesions and follow a variety of local migratory cues in order to
colonize the ovary and establish a primary HGSOC tumor. The ovary seems to facilitate the expansion and
spread of the ovary to the rest of the peritoneal space. Though this phenomenon is well documented, the
molecular mechanisms that drive the initial dissemination of dysplastic fallopian tube cells to the ovary are
poorly understood. To address this, our group has developed a new imaging mass spectrometry technique that
has allowed for unprecedented insight into the paracrine factors that create a pro-metastatic niche and allow
for the migration of fallopian tube cells toward the ovary. Using this technique, we determined that co-culture of
murine ovary explants with dysplastic tubal cells leads to consistent increases in norepinephrine secretion from
the ovary, later found to be produced by the ovary itself. This is significant, as norepinephrine is an established
tumor promoter in advanced disease, and ovarian cancer patients taking β-blockers that interfere with
norepinephrine signals typically have improved clinical outcomes. However, the role of norepinephrine in tumor
development is largely unknown. Given the wide availability, low cost, and minimal adverse effects of β-
blockers, should norepinephrine similarly enhance the development of HGSOC this may provide opportunity
for early intervention and/or chemoprevention in high-risk patients. Given the potential to directly impact clinical
practice, it is essential to further dissect both the mechanisms that direct norepinephrine biosynthesis, as well
as the downstream effects of norepinephrine during HGSOC development. Through the experiments detailed
in this proposal, we will gain valuable insight into these events in hopes of either preventing or delaying
HGSOC development in high-risk patients.
Public Health Relevance Statement
Project Narrative
High grade serous ovarian cancer (HGSOC) has a dismal prognosis, largely attributed to late diagnosis and
poor responses to standard of care treatment. It is therefore essential to better understand the mechanisms of
HGSOC development in order to identify potential strategies for early intervention, particularly in high-risk
patients. In this proposal, we outline a series of experiments exploring the relationship between
norepinephrine signaling and fallopian tube derived high grade serous cancer spread to the ovary in hopes of
developing a new strategy to prevent or delay the development of HGSOC, ultimately improving clinical
outcomes.
No Sub Projects information available for 5F30CA260791-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30CA260791-04
Patents
No Patents information available for 5F30CA260791-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30CA260791-04
Clinical Studies
No Clinical Studies information available for 5F30CA260791-04
News and More
Related News Releases
No news release information available for 5F30CA260791-04
History
No Historical information available for 5F30CA260791-04
Similar Projects
No Similar Projects information available for 5F30CA260791-04